Sunitinib First-line Treatment in Metastatic Renal Cell Carcinoma: Costs and Effects

Abstract

The main cost during sunitinib treatment of mRCC was the drug itself (73% of the total costs). Drug costs and HRQoL should be considered when choosing treatment for mRCC.